Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Sandra Lassalle
Based on 5 articles published since 2010
(Why 5 articles?)
||||

Between 2010 and 2020, S. Lassalle wrote the following 5 articles about Melanoma.
 
+ Citations + Abstracts
1 Review [Focus on clinical and pathological management of conjunctival melanocytic tumors]. 2018

Lassalle, Sandra / Caujolle, Jean-Pierre / Leger, François / Maschi, Célia / Gastaud, Lauris / Nahon-Esteve, Sacha / Thariat, Juliette / Baillif, Stéphanie / Hofman, Paul. ·Laboratoire de pathologie clinique et expérimentale, pavillon J, hôpital Pasteur, CHU de Nice, 30, voie Romaine, CS 51069, 06001 Nice cedex 1, France; Institute of research on cancer and aging de Nice (IRCAN), Inserm U1081/CNRS UMR7284, UFR de médecine, 28, avenue Valombrose, 06107 Nice cedex 2, France; FHU OncoAge Nice, 30, avenue de la voie Romaine, CS 51069, 06001 Nice cedex 1, France. Electronic address: lassalle.s@chu-nice.fr. · Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, CS 51069, 06001 Nice cedex 1, France. · Service de pathologie, hôpital Pellegrin, CHU de Bordeaux, 33000 Bordeaux, France. · Département d'oncologie médicale, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice, France. · Département de radiothérapie, centre Antoine-Lacassagne, 33, avenue Valombrose, 06189 Nice, France. · Laboratoire de pathologie clinique et expérimentale, pavillon J, hôpital Pasteur, CHU de Nice, 30, voie Romaine, CS 51069, 06001 Nice cedex 1, France; Institute of research on cancer and aging de Nice (IRCAN), Inserm U1081/CNRS UMR7284, UFR de médecine, 28, avenue Valombrose, 06107 Nice cedex 2, France; FHU OncoAge Nice, 30, avenue de la voie Romaine, CS 51069, 06001 Nice cedex 1, France. ·Ann Pathol · Pubmed #29803361.

ABSTRACT: Conjunctival-pigmented tumors are rare, but they are one of the most commonly encountered by the pathologist working with the department of ophthalmology. Nevus and melanoma can be encountered and have some histological difference compared to their cutaneous counterpart. Primary acquired melanosis (PAM) is a conjunctival specific entity. This clinical term includes several histological lesions ranging from benignity to melanoma precursor lesion. Histologic examination determines the therapy and the risk of progression to melanoma. We present here a histopathological, clinical and therapeutic synthesis of conjunctival-pigmented lesions, emphasizing the importance of a good understanding between clinicians and pathologists.

2 Article Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas. 2019

Thariat, Juliette / Salleron, Julia / Maschi, Celia / Fevrier, Edouard / Lassalle, Sandra / Gastaud, Lauris / Baillif, Stephanie / Claren, Audrey / Baumard, Florent / Herault, Joel / Caujolle, Jean Pierre. ·Department of Radiation Oncology, Francois Baclesse Cancer ARCHADE Center, Normandie Universite-Unicaen, 3 Av General Harris, 14000, Caen, France. jthariat@gmail.com. · Laboratoire de physique corpusculaire IN2P3/ENSICAEN - UMR6534, 3 Av Genenral Harris, 14000, Caen, France. jthariat@gmail.com. · Department of Biostatistics, Institut de Cancérologie de Lorraine, Université de Lorraine, F-54500, Vandœuvre-lès-Nancy, France. · Department of Ophthalmology, Pasteur 2 Teaching Hospital, Nice, France. · Department of biopathology, Pasteur 2 Teaching Hospital, Nice, France. · Department of Medical Oncology, Antoine-Lacassagne Cancer Center, Nice, France. · Department of Radiation Oncology, Antoine-Lacassagne Cancer Center, Nice, France. ·Radiat Oncol · Pubmed #31881977.

ABSTRACT: INTRODUCTION: conjunctival melanomas have high local relapse rates. Oncologic and visual outcomes can be improved with proton therapy and no-touch surgery. MATERIAL AND METHODS: a monocentric retrospective study of consecutive patients treated with surgery and proton therapy for conjunctival melanoma was conducted. Proton therapy was performed to a total dose of 45 Grays physical dose delivered in eight fractions over two weeks. RESULTS: Ninety-two patients were included. The mean age was 63-year-old. 65.2% of patients had primary acquired melanosis. The mean tumor thickness and diameter was 2.5 mm and 7.0 mm respectively. The clinical stage was T1 in 71.6% of cases, with a quadrangular involvement of more than 90° in 69% of cases. Conjunctival melanomas were of epithelioid cell-type in 40% of cases. Mean follow-up was 4.7 years. Five-year local failure rate was 33.2%. Of 25 local recurrences, 14 were marginal/out-of-field, 4 in-field, others were undetermined. First surgery at expert center resulted in 24.3% of local failure at 5 years versus 38.7% if performed elsewhere (p = 0.41). Salvage exenteration was performed in 13 patients. Tumor stage and quadrangular involvement were significant factors for local failure. Five-year progression-free survival and cause-specific death rates were 61.5 and 3.6%. Stage and epithelioid type were associated with poorer progression-free survival. Trophic toxicity occurred in 22.9% of patients and was treated locally, with grafts in 7 patients. Glaucoma and cataract occurred in 13 and 22 patients respectively. Prognostic factors for visual deterioration were age, tumor extent (multifocality, quadrangular involvement > 180°) and cryotherapy. CONCLUSIONS: 5-year local failure rate after postoperative proton therapy for conjunctival melanoma was of 33.2%. Radiation-induced complications were overall manageable.

3 Article [Local, regional and systemic dissemination of choroidal melanoma : Clinical and pathological correlation from 2 cases]. 2019

Martel, A / Lassalle, S / Gastaud, L / Maschi, C / Caujolle, J P / Nahon-Esteve, S. ·Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, avenue Voie Romaine, 06000 Nice, France; Université Côte d'Azur, 06000 Nice, France; Inserm U 1065, centre Méditerranéen de médecine moléculaire (C3M), équipe 1, 06000 Nice, France. Electronic address: arnaudmartel@hotmail.fr. · Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, avenue Voie Romaine, 06000 Nice, France; Service d'anatomopathologie, hôpital Pasteur 1, CHU de Nice, 06000 Nice, France. · Service d'oncologie médicale, centre Antoine-Lacassagne, 06000 Nice, France. · Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, avenue Voie Romaine, 06000 Nice, France. · Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, avenue Voie Romaine, 06000 Nice, France; Université Côte d'Azur, 06000 Nice, France. ·J Fr Ophtalmol · Pubmed #31196663.

ABSTRACT: PURPOSE: To describe didactically the local, regional and systemic spread of choroidal melanoma. PATIENTS AND METHODS: Two patients who had undergone primary enucleation for the management of choroidal melanoma in 2018 at the University Hospital of Nice were included. Extrascleral extension and invasion of the vortex veins were evaluated, as well as synchronous and metachronous metastases, based on our database. RESULTS: Patient 1 was diagnosed with large choroidal melanoma with partial scleral invasion and vortex vein involvement. Cytogenetic analysis demonstrated a loss of chromosome 3, and a gain of chromosome 8q. Systemic work-up was unremarkable. Patient 2 was diagnosed with a large choroidal melanoma with extrascleral extension and vortex vein involvement. Cytogenetic analysis demonstrated a loss of chromosome 3 and a gain of chromosome 8q. Systemic work-up revealed several liver metastases. A total of 1762 patients were included in our database. Eighty-five patients (4.8 %) and 46 patients (2.6 %) experienced vortex vein invasion and extrascleral extension respectively. Patients with vortex vein invasion were diagnosed with synchronous and metachronous liver metastases in 1.2 % and 18.8 % respectively. Patients with extrascleral extension had synchronous and metachronous liver metastases in 6.5 % and 30.4 % respectively. The mean follow-up was 49.4 months (1-180). CONCLUSION: Extrascleral extension and vortex vein invasion illustrate the local, regional and systemic spread of choroidal melanoma. The latter are often associated with genetically aggressive tumours associated with high metastatic risk.

4 Article Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). 2015

Long, E / Ilie, M / Lassalle, S / Butori, C / Poissonnet, G / Washetine, K / Mouroux, J / Lespinet, V / Lacour, J P / Taly, V / Laurent-Puig, P / Bahadoran, P / Hofman, V / Hofman, P. ·Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice Cedex, France. · Institute for Research on Cancer and Aging, Nice (IRCAN) CNRS UMR 7284/Inserm U1081, University of Nice Sophia Antipolis, Nice, France. · Department of Surgery, CLCC Antoine Lacassagne Center, Nice, France. · Nice Hospital-Related Biobank BB-0033-00025, Pasteur Hospital, Nice, France. · Department of Thoracic Surgery, Pasteur Hospital, Nice, France. · Department of Dermatology, Archet Hospital, Nice, France. · INSERM UMR-S1147, Centre Universitaire des Saints-Pères, University Paris Sorbonne Cité, Paris, France. ·J Eur Acad Dermatol Venereol · Pubmed #26377147.

ABSTRACT: BACKGROUND: Knowledge of the BRAFV600E status is mandatory in metastatic melanoma patients (MMP). Molecular biology is currently the gold standard method for status assessment. OBJECTIVES: We assessed and compared the specificity, sensibility, cost-effectiveness and turnaround time (TAT) of immunohistochemistry (IHC) and molecular biology for detection of the BRAFV600E mutation in 188 MMP. METHODS: IHC, with the VE1 antibody, and pyrosequencing analysis were performed with formalin fixed paraffin embedded tumour samples. RESULTS: The BRAFV600E mutation was detected by pyrosequencing in 91/188 (48%) patients. IHC was strongly positive (3+) in all of these 91 cases. IHC was strongly positive in 9/188 (5%) cases in which the molecular testing failed due to non-amplifiable DNA. Weak or moderate staining was noted in 10/188 (5%) cases in which the molecular biology identified BRAF wild-type tumours. The ratio of the global cost for IHC/molecular biology testing was 1 : 2.2. The average TAT was 48 h vs. 96 h, for IHC vs. molecular biology testing, respectively. CONCLUSIONS: This study showed that VE1 IHC should be a substitute for molecular biology in the initial assessment of the BRAFV600E status in MPP. This methodology needs to be set up in pathology laboratories in accordance with quality control/quality assurance accreditation procedures. Under these strict conditions the question is to know if BRAFV600E-IHC can serve not only as a prescreening tool, but also as a stand-alone test (at least in cases displaying an unequivocally staining pattern) as well as an alternative predictive test for samples for which the molecular biology failed.

5 Article Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. 2015

Ilie, Marius / Long-Mira, Elodie / Funck-Brentano, Elisa / Lassalle, Sandra / Butori, Catherine / Lespinet-Fabre, Virginie / Bordone, Olivier / Gay, Alexandre / Zahaf, Katia / Poissonnet, Gilles / Lacour, Jean-Philippe / Bahadoran, Philippe / Ballotti, Robert / Gros, Audrey / Dutriaux, Caroline / Saiag, Philippe / Merlio, Jean-Philippe / Vergier, Béatrice / Emile, Jean François / Hofman, Véronique / Hofman, Paul. ·Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France. · Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France. · EA4340-Biomarqueurs en Cancérologie et Onco-Hématologie (BCOH), University of Versailles Saint-Quentin-en-Yvelines (SQY), Boulogne, France; Department of General and Oncologic Dermatology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France. · Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France. · Surgery Department, Comprehensive Cancer Center Antoine Lacassagne, Nice, France. · Dermatology Department, Archet II Hospital, Nice, France. · Dermatology Department, Archet II Hospital, Nice, France; Institut National de la Santé et de la Recherche Médicale (INSERM) U1065, Team 1, University of Nice Sophia Antipolis, Nice, France. · Institut National de la Santé et de la Recherche Médicale (INSERM) U1065, Team 1, University of Nice Sophia Antipolis, Nice, France. · Pathology and Molecular Biology Departments, Centre Hospitalier Universitaire (CHU) and EA2406 University of Bordeaux, Bordeaux, France. · Department of Oncologic Dermatology, CHU Bordeaux, Bordeaux, France. · EA4340-Biomarqueurs en Cancérologie et Onco-Hématologie (BCOH), University of Versailles Saint-Quentin-en-Yvelines (SQY), Boulogne, France; Department of Pathology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Boulogne, France. · Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; Human Biobank BB-0033-00025, Pasteur Hospital, Nice, France. Electronic address: hofman.p@chu-nice.fr. ·J Am Acad Dermatol · Pubmed #25659223.

ABSTRACT: BACKGROUND: It can be useful to assess the NRAS mutation status in patients with metastatic melanoma because NRAS-activating mutations confer resistance to RAF inhibitors, and NRAS-mutated patients appear to be sensitive to mitogen-activated protein kinase (MEK) inhibitors. OBJECTIVE: We aimed to assess the diagnostic accuracy of an immunohistochemistry (IHC) approach using a novel anti-NRAS (Q61R) monoclonal antibody on formalin-fixed paraffin-embedded tissue samples from patients with metastatic melanoma. METHODS: We conducted a retrospective multicenter cohort study on 170 patients with metastatic melanoma. The automated IHC assay was performed using the SP174 clone, and compared with results of the molecular testing. RESULTS: Evaluation of a test cohort with knowledge of the mutation status established a specific IHC pattern for the mutation. In the independent blinded analysis of the remaining cases, the anti-NRAS (Q61R) antibody accurately identified all NRAS Q61R-mutated tumors, and demonstrated 100% sensitivity and specificity. LIMITATIONS: Limitations include retrospective design and lack of multicenter interobserver reproducibility. CONCLUSION: The NRAS (Q61R) IHC assay is reliable and specific for the evaluation of the Q61R mutation status in metastatic melanoma and may be an alternative to molecular biology in evaluation of metastatic melanoma in routine practice.